Are ocular complications of a high-dose glucocorticoid treatment appropriately monitored in patients with rheumatic diseases?

By Han Bobby   Yachoui Ralph   Yi Kayoung  

Rheumatology International, Vol. 33, Iss. 11, 2013-11 ,pp. : 2951-2952

Springer Publishing Company

Access to resources Recommend Favorite

Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study

By Konttinen Liisa   Kankaanpää Eeva   Luosujärvi Riitta   Blåfield Harri   Vuori Kaisa   Hakala Markku   Rantalaiho Vappu   Savolainen Elina   Uutela Toini   Nordström Dan  

Clinical Rheumatology, Vol. 25, Iss. 6, 2006-11 ,pp. : 882-884

Springer Publishing Company

Access to resources Recommend Favorite

Ocular Vascular Involvement in the Rheumatic Diseases

By  

Current Rheumatology Reviews, Vol. 7, Iss. 1, 2011-02 ,pp. : 39-50

Bentham Science Publishers

Access to resources Recommend Favorite

Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis

By Rodriguez-Rodriguez L   Jover-Jover JA   Fontsere O   Peña-Blanco RC   León L   Fernández-Gutierrez B   Abásolo L  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 6, 2013-11 ,pp. : 433-436

Informa Healthcare

Access to resources Recommend Favorite

Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up

By Tiippana-Kinnunen T   Paimela L   Kautiainen H   Laasonen L   Leirisalo-Repo M  

Scandinavian Journal of Rheumatology, Vol. 39, Iss. 1, 2010-05 ,pp. : 12-18

Informa Healthcare

Access to resources Recommend Favorite